Absci in May made the leap to become a clinical company, according to an internal memo seen by Fierce. At the end of the second quarter, Fate had cash, cash equivalents and investments worth $248.9 million. As of March 31, Precision had around $100 million in cash, cash equivalents and restricted cash. Prothena had $418.8 million in cash, cash equivalents and restricted cash as of March 31, 2025. As of March 31, the company had $418.8 million in cash, cash equivalents and restricted cash with no debt.